+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmaceutical Services Outsourcing Market - Global Forecast 2026-2032- Product Image
Pharmaceutical Services Outsourcing Market - Global Forecast 2026-2032- Product Image
Sale

Pharmaceutical Services Outsourcing Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5639460
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pharmaceutical Services Outsourcing Market is projected to reach USD 95.47 Billion in 2026. It is expected to continue growing at a CAGR of 7.82%, reaching USD 152.16 Billion by 2032.

Pharmaceutical services outsourcing has become a core operating model for biopharmaceutical companies seeking faster development timelines, compliant manufacturing capacity, specialized regulatory expertise, and scalable commercialization support. The industry spans contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), contract manufacturing organizations (CMOs), pharmacovigilance providers, regulatory affairs partners, clinical trial service firms, and commercial support specialists.

Demand is supported by sustained global medicine use, expanding biologics and specialty-drug pipelines, and the increasing complexity of clinical development and manufacturing. Verified indicators from regulators, clinical trial registries, pharmacopeial bodies, and multilateral health institutions show that drug developers are operating in a more demanding environment shaped by stricter quality expectations, diversified trial geographies, supply chain resilience requirements, and growing reliance on external partners with advanced scientific, digital, and compliance capabilities.

Transformative Shifts in the Outsourcing Landscape

The pharmaceutical services outsourcing landscape is shifting from transactional vendor management to strategic, integrated partnerships. Sponsors are increasingly selecting outsourcing partners that can combine discovery support, clinical operations, regulatory strategy, analytical development, sterile fill-finish, biologics manufacturing, packaging, serialization, pharmacovigilance, and real-world evidence capabilities within globally compliant platforms.

Transformative change is being driven by the rise of biologics, cell and gene therapies, high-potency active pharmaceutical ingredients, decentralized clinical trial models, and demand for flexible manufacturing networks. Regulatory expectations from agencies such as the U.S. FDA, EMA, and national health authorities continue to emphasize data integrity, quality-by-design, validated systems, patient safety, and inspection readiness, pushing service providers to invest in automation, digital quality management, advanced analytics, and resilient supply chains.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is reshaping pharmaceutical services outsourcing by improving target identification, protocol design, site selection, patient recruitment, medical writing, pharmacovigilance signal detection, demand planning, batch analytics, and quality deviation management. In outsourced clinical and manufacturing workflows, AI is most valuable when combined with validated data governance, human oversight, audit trails, and regulatory-grade documentation.

The cumulative impact is a movement toward faster decision-making and more predictive operations across the outsourcing value chain. CROs are using AI-enabled analytics to reduce trial inefficiencies, while CDMOs are applying machine learning to process optimization, predictive maintenance, and release-quality review. Adoption must remain aligned with evolving guidance on computerized systems, privacy protection, model transparency, cybersecurity, good machine learning practice, and responsible use of generative AI in regulated life sciences environments.

Key Regional Insights Across Global Markets

Asia-Pacific is gaining prominence in pharmaceutical services outsourcing due to cost-competitive research operations, expanding clinical trial participation, strong generic drug manufacturing, and growing biologics capacity in China, India, Japan, South Korea, Australia, and ASEAN economies. Regional momentum is supported by large patient populations, improving regulatory maturity, increased investment in biomanufacturing and clinical infrastructure, and government initiatives that encourage domestic medicine production and advanced therapy development.

North America remains a leading hub for high-value outsourcing, supported by the United States and Canada’s deep biotech ecosystem, FDA-regulated development pathways, advanced CDMO capacity, and strong demand for clinical trial outsourcing, pharmacovigilance outsourcing, regulatory affairs support, and specialty manufacturing. Europe continues to offer scientific depth, EMA-aligned quality standards, well-established pharmacovigilance systems, and strong demand for specialized manufacturing and clinical services, particularly across the European Union, the United Kingdom, Germany, France, Italy, and Spain.

Latin America is increasingly relevant for clinical trial services, regulatory support, and market access activities, with Brazil and Mexico offering large patient pools, established healthcare systems, and regional logistics advantages. The Middle East is investing in pharmaceutical localization, medicine security, and healthcare infrastructure, particularly across GCC markets, while Africa is emerging as a long-term opportunity for clinical research networks, supply chain strengthening, vaccine access, and local manufacturing partnerships tied to public health priorities.

Key Group Insights for Strategic Outsourcing

ASEAN is becoming more attractive for pharmaceutical outsourcing as member economies strengthen regulatory cooperation, expand healthcare access, and build clinical research and manufacturing capabilities. The region offers advantages in patient diversity, competitive operating costs, and improving logistics, making it relevant for clinical trial outsourcing, packaging, technology transfer, and regional distribution support.

The GCC is prioritizing healthcare modernization, medicine security, and pharmaceutical localization, creating opportunities for CDMOs, regulatory consultants, serialization providers, and technology-enabled service partners. The European Union remains one of the world’s most sophisticated regulated markets, with harmonized pharmacovigilance, clinical trial, and manufacturing standards that support demand for compliant outsourcing partners able to meet stringent quality and data integrity requirements.

BRICS economies provide scale, manufacturing strength, scientific talent, and large patient populations, making them central to drug development outsourcing and global supply strategies. G7 markets continue to lead in innovation, regulatory science, advanced manufacturing, and high-value biopharmaceutical services, while NATO countries emphasize secure supply chains, critical medicine availability, cybersecurity, and resilient health systems, reinforcing the importance of trusted outsourcing partners.

Key Country Insights in Pharmaceutical Outsourcing

The United States leads in pharmaceutical services outsourcing due to its concentration of biotechnology companies, advanced clinical trial networks, FDA-regulated innovation pathways, and strong demand for specialized CRO and CDMO services. Canada offers a stable research environment, recognized clinical trial capabilities, and growing biomanufacturing investment, while Mexico supports nearshore manufacturing, packaging, logistics, and clinical operations for North American supply chains. Brazil’s scale, diverse patient population, and healthcare infrastructure make it an important Latin American market for clinical research, pharmacovigilance, and regulatory services.

In Europe, the United Kingdom remains a strong center for clinical research, life sciences investment, early-stage development, and regulatory expertise. Germany and France combine pharmaceutical innovation with advanced manufacturing and quality systems, while Italy and Spain provide strong clinical trial participation, established production capabilities, and access to experienced investigator networks. Russia retains domestic pharmaceutical capacity, but geopolitical, sanctions-related, and compliance considerations continue to influence outsourcing decisions.

China and India are pivotal to global pharmaceutical outsourcing, with China expanding biologics, discovery, clinical research, and advanced manufacturing capabilities, and India maintaining strength in generics, APIs, clinical services, pharmacovigilance, and regulatory support. Japan offers high-quality development and regulatory expertise in a mature healthcare environment, Australia is valued for early-phase clinical trials and strong research infrastructure, and South Korea has become a major biologics CDMO and clinical development hub supported by advanced technology, skilled talent, and government-backed life sciences investment.

Actionable Recommendations for Industry Leaders

Industry leaders should treat pharmaceutical services outsourcing as a strategic capability rather than a cost-reduction tactic. Sponsors should evaluate partners on regulatory track record, therapeutic expertise, inspection history, digital maturity, data integrity controls, cybersecurity posture, quality culture, supply continuity, scientific specialization, and ability to scale from development through commercialization.

Executives should diversify supplier networks, qualify dual-source options for critical materials, and build governance models with clear quality agreements, performance metrics, escalation pathways, audit schedules, and business continuity plans. Companies should also prioritize partners with validated AI and automation capabilities, robust pharmacovigilance systems, transparent ESG practices, secure data environments, and experience across major regulatory jurisdictions to support faster approvals and resilient global operations.

Research Methodology

This executive summary is developed using a structured secondary research approach aligned with market intelligence best practices. The analysis draws on verified public sources such as regulatory agency publications, clinical trial registries, pharmacopeial references, national health statistics, trade association materials, peer-reviewed literature, inspection guidance, and policy documents from recognized health and economic institutions.

Findings are triangulated across demand-side indicators, supply-side capacity signals, regulatory developments, technology adoption trends, regional policy shifts, and competitive positioning. The methodology emphasizes data validation, source credibility, recency, and relevance to pharmaceutical services outsourcing, including CRO, CDMO, CMO, regulatory affairs, pharmacovigilance, clinical trial, manufacturing, packaging, analytical testing, quality assurance, and commercialization service segments.

Conclusion

Pharmaceutical services outsourcing is entering a more strategic phase as drug developers seek specialized expertise, flexible capacity, faster execution, and regulatory confidence across the product life cycle. Momentum is being reinforced by complex therapies, globalized clinical trials, digital quality systems, AI-enabled workflows, and the need for resilient manufacturing and supply chains.

Organizations that select outsourcing partners based on scientific capability, compliance strength, technology readiness, and geographic alignment will be better positioned to accelerate development, reduce operational risk, and compete in a demanding global pharmaceutical environment. The strongest opportunities will favor service providers that combine regulatory credibility, advanced analytics, scalable infrastructure, secure data practices, and measurable quality performance.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Pharmaceutical Services Outsourcing Market, by Service Type
7.1. Introduction
7.2. Clinical Development
7.2.1. Phase I
7.2.2. Phase II
7.2.3. Phase III
7.2.4. Post Marketing
7.2.5. Preclinical
7.3. Data Management
7.3.1. Data Integration
7.3.2. Edc Solutions
7.3.2.1. Cloud Based
7.3.2.2. On Premise
7.3.3. Medical Coding
7.3.4. Statistical Programming
7.4. Manufacturing Services
7.4.1. Biologic Manufacturing
7.4.2. Drug Product Manufacturing
7.4.3. Drug Substance Manufacturing
7.4.4. Fill Finish
7.4.5. Formulation Development
7.5. Pharmacovigilance
7.5.1. Aggregate Reporting
7.5.2. Case Processing
7.5.3. Risk Management
7.5.4. Signal Detection
7.6. Regulatory Affairs
7.6.1. Audit Support
7.6.2. Dossier Preparation
7.6.3. Labeling Compliance
7.6.4. Submission Management
8. Pharmaceutical Services Outsourcing Market, by Clinical Phase
8.1. Introduction
8.2. Phase I
8.2.1. Multiple Ascending Dose
8.2.2. Single Ascending Dose
8.3. Phase II
8.3.1. Phase IIa
8.3.2. Phase IIb
8.4. Phase III
8.5. Post Marketing
8.6. Preclinical
9. Pharmaceutical Services Outsourcing Market, by Therapeutic Area
9.1. Introduction
9.2. Cardiovascular
9.3. Infectious Diseases
9.4. Neurology
9.5. Oncology
9.5.1. Hematological Malignancies
9.5.2. Solid Tumors
10. Pharmaceutical Services Outsourcing Market, by Molecule Type
10.1. Introduction
10.2. Small Molecules
10.3. Biologics
10.3.1. Monoclonal antibodies
10.3.2. Recombinant proteins
10.4. Cell and Gene Therapy
10.5. Vaccines
10.6. Biosimilars
11. Pharmaceutical Services Outsourcing Market, by End User
11.1. Introduction
11.2. Biotechnology Companies
11.3. Generic Drug Manufacturers
11.4. Pharmaceutical Companies
11.5. Government organizations
12. Pharmaceutical Services Outsourcing Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Pharmaceutical Services Outsourcing Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Pharmaceutical Services Outsourcing Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AmerisourceBergen Corporation
16.2. Catalent, Inc.
16.3. CEVA Logistics AG
16.4. Charles River Laboratories, Inc.
16.5. Concept Heidelberg GmbH
16.6. Curia Global, Inc.
16.7. Dalton Pharma Services by Seikagaku Corporation
16.8. DHL International GmbH
16.9. Eurofins Scientific (Ireland) Limited
16.10. Evotec SE
16.11. GenScript Biotech Corporation
16.12. Icon PLC
16.13. IQVIA HOLDINGS, INC.
16.14. Laboratory Corporation of America Holdings
16.15. Lachman Consultant Services, Inc.
16.16. McKesson Corporation by Aurelius Group
16.17. Medpace Holdings, Inc.
16.18. Parexel International Corporation
16.19. Syneos Health, Inc.
16.20. Thermo Fisher Scientific Inc.
16.21. WuXi AppTec Co., Ltd.
List of Figures
FIGURE 1. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL PHASE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL PHASE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL PHASE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL PHASE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL POST MARKETING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL POST MARKETING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL POST MARKETING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PRECLINICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL PRECLINICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL PRECLINICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL DATA MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL DATA MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL DATA MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL DATA INTEGRATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL DATA INTEGRATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL DATA INTEGRATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL EDC SOLUTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL EDC SOLUTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL EDC SOLUTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CLOUD BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CLOUD BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CLOUD BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ON PREMISE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ON PREMISE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ON PREMISE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MEDICAL CODING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL MEDICAL CODING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL MEDICAL CODING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL STATISTICAL PROGRAMMING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL STATISTICAL PROGRAMMING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL STATISTICAL PROGRAMMING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL BIOLOGIC MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL BIOLOGIC MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL BIOLOGIC MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL DRUG PRODUCT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL DRUG PRODUCT MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL DRUG PRODUCT MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL DRUG SUBSTANCE MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL DRUG SUBSTANCE MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL DRUG SUBSTANCE MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL FILL FINISH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL FILL FINISH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL FILL FINISH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL AGGREGATE REPORTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL AGGREGATE REPORTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL AGGREGATE REPORTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL CASE PROCESSING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CASE PROCESSING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL CASE PROCESSING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL RISK MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL RISK MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL RISK MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SIGNAL DETECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SIGNAL DETECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL SIGNAL DETECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL REGULATORY AFFAIRS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL REGULATORY AFFAIRS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL REGULATORY AFFAIRS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL AUDIT SUPPORT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL AUDIT SUPPORT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL AUDIT SUPPORT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL DOSSIER PREPARATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL DOSSIER PREPARATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL DOSSIER PREPARATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL LABELING COMPLIANCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL LABELING COMPLIANCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL LABELING COMPLIANCE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL SUBMISSION MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL SUBMISSION MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL SUBMISSION MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL PHASE, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL PHASE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL MULTIPLE ASCENDING DOSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL MULTIPLE ASCENDING DOSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL MULTIPLE ASCENDING DOSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL SINGLE ASCENDING DOSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL SINGLE ASCENDING DOSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL SINGLE ASCENDING DOSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL PHASE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL PHASE IIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL PHASE IIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL PHASE IIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL PHASE IIB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL PHASE IIB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL PHASE IIB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL PHASE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL POST MARKETING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL POST MARKETING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL POST MARKETING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL PRECLINICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL PRECLINICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL PRECLINICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL CELL AND GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL CELL AND GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL CELL AND GENE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL GENERIC DRUG MANUFACTURERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL GENERIC DRUG MANUFACTURERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL GENERIC DRUG MANUFACTURERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL GOVERNMENT ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 171. GLOBAL GOVERNMENT ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL GOVERNMENT ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 173. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY EDC SOLUTIONS, 2017-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, 2017-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS, 2017-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL PHASE, 2017-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, 2017-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 190. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 191. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 192. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 193. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 194. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY EDC SOLUTIONS, 2017-2032 (USD MILLION)
TABLE 195. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 196. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, 2017-2032 (USD MILLION)
TABLE 197. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS, 2017-2032 (USD MILLION)
TABLE 198. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL PHASE, 2017-2032 (USD MILLION)
TABLE 199. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, 2017-2032 (USD MILLION)
TABLE 200. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 201. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 202. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 203. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 204. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 205. NORTH AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 206. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 207. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 208. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 209. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 210. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY EDC SOLUTIONS, 2017-2032 (USD MILLION)
TABLE 211. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 212. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, 2017-2032 (USD MILLION)
TABLE 213. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS, 2017-2032 (USD MILLION)
TABLE 214. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL PHASE, 2017-2032 (USD MILLION)
TABLE 215. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, 2017-2032 (USD MILLION)
TABLE 216. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 217. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 218. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 219. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 220. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 221. LATIN AMERICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 223. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 224. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 225. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 226. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY EDC SOLUTIONS, 2017-2032 (USD MILLION)
TABLE 227. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 228. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, 2017-2032 (USD MILLION)
TABLE 229. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS, 2017-2032 (USD MILLION)
TABLE 230. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL PHASE, 2017-2032 (USD MILLION)
TABLE 231. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, 2017-2032 (USD MILLION)
TABLE 232. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 233. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 234. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 235. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 236. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 237. EUROPE PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 238. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 239. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 240. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 241. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 242. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY EDC SOLUTIONS, 2017-2032 (USD MILLION)
TABLE 243. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 244. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, 2017-2032 (USD MILLION)
TABLE 245. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS, 2017-2032 (USD MILLION)
TABLE 246. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL PHASE, 2017-2032 (USD MILLION)
TABLE 247. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, 2017-2032 (USD MILLION)
TABLE 248. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 249. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 250. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 251. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 252. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 253. MIDDLE EAST PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 255. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 256. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 257. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 258. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY EDC SOLUTIONS, 2017-2032 (USD MILLION)
TABLE 259. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 260. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, 2017-2032 (USD MILLION)
TABLE 261. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS, 2017-2032 (USD MILLION)
TABLE 262. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL PHASE, 2017-2032 (USD MILLION)
TABLE 263. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, 2017-2032 (USD MILLION)
TABLE 264. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 265. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 266. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 267. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 268. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 269. AFRICA PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 270. GLOBAL PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 271. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 272. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 273. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 274. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 275. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY EDC SOLUTIONS, 2017-2032 (USD MILLION)
TABLE 276. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 277. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, 2017-2032 (USD MILLION)
TABLE 278. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS, 2017-2032 (USD MILLION)
TABLE 279. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL PHASE, 2017-2032 (USD MILLION)
TABLE 280. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, 2017-2032 (USD MILLION)
TABLE 281. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 282. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 283. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 284. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 285. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 286. ASEAN PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 287. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 288. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 289. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 290. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 291. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY EDC SOLUTIONS, 2017-2032 (USD MILLION)
TABLE 292. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 293. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, 2017-2032 (USD MILLION)
TABLE 294. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS, 2017-2032 (USD MILLION)
TABLE 295. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL PHASE, 2017-2032 (USD MILLION)
TABLE 296. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, 2017-2032 (USD MILLION)
TABLE 297. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 298. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 299. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 300. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 301. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 302. GCC PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 304. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 305. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 306. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 307. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY EDC SOLUTIONS, 2017-2032 (USD MILLION)
TABLE 308. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 309. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, 2017-2032 (USD MILLION)
TABLE 310. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS, 2017-2032 (USD MILLION)
TABLE 311. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL PHASE, 2017-2032 (USD MILLION)
TABLE 312. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, 2017-2032 (USD MILLION)
TABLE 313. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 314. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 315. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 316. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 317. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 318. EUROPEAN UNION PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 319. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 320. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 321. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 322. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 323. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY EDC SOLUTIONS, 2017-2032 (USD MILLION)
TABLE 324. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 325. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, 2017-2032 (USD MILLION)
TABLE 326. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS, 2017-2032 (USD MILLION)
TABLE 327. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL PHASE, 2017-2032 (USD MILLION)
TABLE 328. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, 2017-2032 (USD MILLION)
TABLE 329. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 330. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 331. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 332. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 333. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 334. BRICS PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 335. G7 PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 336. G7 PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 337. G7 PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 338. G7 PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT, 2017-203

Companies Mentioned

  • AmerisourceBergen Corporation
  • Catalent, Inc.
  • CEVA Logistics AG
  • Charles River Laboratories, Inc.
  • Concept Heidelberg GmbH
  • Curia Global, Inc.
  • Dalton Pharma Services by Seikagaku Corporation
  • DHL International GmbH
  • Eurofins Scientific (Ireland) Limited
  • Evotec SE
  • GenScript Biotech Corporation
  • Icon PLC
  • IQVIA HOLDINGS, INC.
  • Laboratory Corporation of America Holdings
  • Lachman Consultant Services, Inc.
  • McKesson Corporation by Aurelius Group
  • Medpace Holdings, Inc.
  • Parexel International Corporation
  • Syneos Health, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages194
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 95.47 Billion
Forecasted Market Value ( USD ) by 2032 $ 152.16 Billion
Compound Annual Growth Rate7.8%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Biotechnology & Pharmaceutical Services Outsourcing Market - Global Forecast 2026-2032 - Product Image

Biotechnology & Pharmaceutical Services Outsourcing Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Biotechnology / Pharmaceutical Services Outsourcing - Global Strategic Business Report - Product Image

Biotechnology / Pharmaceutical Services Outsourcing - Global Strategic Business Report

  • Report
  • 292 Pages
  • Global
From
Advanced Therapeutics Pharmaceutical Outsourcing Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Advanced Therapeutics Pharmaceutical Outsourcing Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Biotechnology and Pharmaceutical Services Outsourcing Market Report 2026 - Product Image

Biotechnology and Pharmaceutical Services Outsourcing Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Formulation Development Outsourcing Market - Global Forecast 2026-2032 - Product Image

Formulation Development Outsourcing Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From

About the Pharmaceutical Services Outsourcing Market

Pharmaceutical Services Outsourcing (PSO) is a rapidly growing market within the pharmaceutical manufacturing industry. It involves the transfer of certain activities, such as drug development, clinical trials, and manufacturing, from pharmaceutical companies to third-party service providers. This allows pharmaceutical companies to focus on their core competencies while outsourcing non-core activities to specialized service providers. PSO also helps pharmaceutical companies reduce costs, increase efficiency, and improve quality. The PSO market is segmented into drug development, clinical trials, and manufacturing services. Drug development services include pre-clinical and clinical research, regulatory affairs, and drug safety. Clinical trials services include clinical trial management, data management, and biostatistics. Manufacturing services include active pharmaceutical ingredient (API) manufacturing, finished dosage form (FDF) manufacturing, and packaging and labeling. Notable companies in the PSO market include Parexel, Quintiles, Covance, PRA Health Sciences, and Charles River Laboratories. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.